Precirix raises EUR 80m in Series B, Gimv further supports the development of precision radiopharmaceuticals
Brussels, Belgium, 16 March 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investor INKEF Capital, alongside Jeito Capital and Forbion Capital Partners. The company’s existing shareholders Gimv, HealthCap, Novo Holdings, Pontifax Venture Capital, V-Bio Ventures, BioMed Partners, as well as the seed investors, continue to support the company and participated in the round.
The proceeds of this financing round will fund the development and expansion of Precirix’ pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study and plans to bring additional novel radiopharmaceuticals to the clinic.
Michaël Vlemmix, Principal in Gimv’s Health & Care platform and board member indicates: “Precirix has made significant progress since its Series A in 2018. The additional financing will allow us to further leverage the radiopharmaceutical platform, diversify the pipeline and continue to advance the clinical developments with a core goal to bring new medicines to patients. Backed by some of the strongest names in our industry, the company holds a solid foundation to further build on its story towards success”.
For more information, please read the full press release from Precirix attached.